Dermatology News: 2007.9

• 2007.9(10) Interobserver reliability of the Nail Psoriasis Severity Index
  Because the Psoriasis Area and Severity Index (PASI) does not consider the severity of nail disease, a scale that assesses the extent of involvement of psoriatic nails is needed. A new grading system, the Nail Psoriasis Severity Index (NAPSI) has been proposed.   |   Read more ...



• 2007.9(9) Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute
  Psoriasis is a lifelong, incurable disease that normally develops before the age of 30 years and affects approximately 1·4% of the Spanish population. Numerous clinical trials have demonstrated the efficacy of efalizumab, a recombinant, humanized, monoclonal antibody, which has been approved for the treatment of moderate-to-severe plaque psoriasis.   |   Read more ...



• 2007.9(8) Long-term treatment of plaque psoriasis with efalizumab: an Italian experience
  Biologic agents are an important new class of drugs, offering targeted treatment for chronic skin diseases such as psoriasis. The biologic therapy efalizumab is an anti-CD11a monoclonal antibody, which was approved by the European regulatory agency in 2004 for the treatment of moderate-to-severe plaque psoriasis...   |   Read more ...



• 2007.9(7) The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital
  Efalizumab (anti-CD11a antibody) targets T cell-mediated steps important in the immunopathogenesis of psoriasis. As efalizumab is intended to be administered on a continuous long-term basis in psoriasis, it is important to share experience concerning issues commonly occurring during its use in real daily practice.   |   Read more ...



• 2007.9(6) Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark
  About 20-30% of patients with chronic plaque psoriasis have severe forms of the disease and require systemic treatment. The long-term use of conventional systemic therapies is limited by toxicity, and many patients are resistant to these treatments...   |   Read more ...



• 2007.9(5) Efalizumab in routine use: a clinical experience
  With the advent of biological therapies, continuous long-term control of psoriasis is now becoming a reality. We report our experience with biologics based on the treatment of more than 550 psoriatic patients with such compounds at our special outpatient care center of Bio-Immunotherapy at the Department of Dermatology of the Medical University of Vienna...   |   Read more ...



• 2007.9(4) Changes in skin barrier function following long-term treatment with moisturizers, a randomized controlled trial
  Moisturizers are commonly used by patients with dry skin conditions as well as people with healthy skin. Previous studies on short-term treatment have shown that moisturizers can weaken or strengthen skin barrier function and also influence skin barrier recovery. However, knowledge of the effects on skin barrier function of long-term treatment with moisturizers is still scarce...   |   Read more ...



• 2007.9(3) Resolution of inflammatory acne vulgaris may involve regulation of CD4+ T-cell responses to Propionibacterium acnes
  Propionibacterium acnes has been strongly implicated in inflammatory acne. However, its role in the disease is unclear. It has been hypothesized that an immune response to P. acnes and/or P. acnes heat shock proteins (HSPs) may play a role in the pathogenesis of inflammatory acne...   |   Read more ...



• 2007.9(2) Histamine prevents apoptosis in human monocytes
  As chronic atopic dermatitis (AD) is associated with activation of circulating and infiltrating monocytes, monocytes are considered to play a pivotal role in the establishment of chronic lesions in AD. Histamine is an important mediator of inflammatory and allergic responses. Although new immunomodulatory functions of histamine have recently become apparent, the effect of histamine on the life span of monocytes remains unclear....   |   Read more ...



• 2007.9(1) Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series
  Newer biological therapies for moderate-to-severe psoriasis are being used more frequently, but unexpected effects may occur. Case presentations: We present a group of 15 patients who developed inflammatory papules while on efalizumab therapy...   |   Read more ...

    Current Year Archive:   Dermatology News 2007   |   Main Archive:   Dermatology News  

The Derm News service provided by the Editorial Consultants of Skin Therapy Letter^© and its founding editor Dr. Stuart Maddin.